Literature DB >> 9606991

Evidence for preferential T cell receptor V beta gene usage and T cell clonal expansion in the synovium of BB rats with early-onset collagen-induced arthritis.

X J Ye1, J Aelion, R O Endres, A H Kang, M A Cremer.   

Abstract

Type II collagen (CII) is a potent arthritogen in the BB rat. To determine whether a restricted group of T cells is involved in the pathogenesis of collagen-induced arthritis, lymphocytes from synovium, peripheral blood, and lymph nodes of arthritic rats were studied for T cell receptor (TCR) V beta gene usage using polymerase chain reaction (PCR). Oligoclonal TCR V beta usage was found only in synovium recovered day 2 post-arthritis onset, but not day 7; lymph node and peripheral blood T cells showed diverse TCR usage at both times. To determine whether T cell local clonal expansion occurred in synovium at day 2 of arthritis, cDNA for four TCR beta families was sequenced through VDJ regions. Strong selective expansion of TCR V beta 8.2, 4, and 17 was noted. Importantly, the dominant clonotype of V beta 8.2 was identical to that of a lymph node-derived T hybridoma specific for the immunodominant epitope in CII(181-210). Cells from synovium (day 2 postonset) analyzed by flow cytometry also showed V beta 8.2+ cell enrichment. These observations, plus finding that T cells from inflamed synovium respond to CII(181-201) in vitro, suggest the local recruitment and clonal expansion of some T cells families, possibly driven by autologous CII released during cartilage degradation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9606991     DOI: 10.1006/cimm.1998.1249

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  2 in total

1.  Antigen presentation of Type II collagen in rats.

Authors:  B Catchpole; N A Staines; A S Hamblin
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

2.  The roles of interleukin-18 in collagen-induced arthritis in the BB rat.

Authors:  X J Ye; B Tang; Z Ma; A H Kang; L K Myers; M A Cremer
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.